ArticleFrontiers in immunology2022
Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.The European respiratory journal · 2026Guideline
- Influencing factors for rapidly progressive interstitial lung disease in patients with anti-MDA5 antibody-positive dermatomyositis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Risk factors for mortality in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Determinants for worsening in systemic autoimmune rheumatic disease-associated interstitial lung disease: a systematic review and meta-analysis of cohort studies.Frontiers in medicine · 2024Pooled it
- Idiopathic inflammatory myopathy-related interstitial lung disease patients present to pulmonology: a tertiary center experience.Annals of the American Thoracic Society · 2026Article
- Clinical features, triggers, and risk factors of severe gastrointestinal involvement in anti-NXP2-positive juvenile dermatomyositis: a retrospective cohort study.Pediatric rheumatology online journal · 2026Article
- Lung transplant outcomes in myositis, systemic sclerosis and idiopathic pulmonary fibrosis: a multicentre retrospective analysis.Rheumatology (Oxford, England) · 2026Article
- Preliminary nomogram model for predicting respiratory failure of patients with idiopathic inflammatory myopathies.Scientific reports · 2026Article
- Clinical characteristics and long-term prognosis of anti-MDA5-positive dermatomyositis: a comparative study across age groups.Orphanet journal of rare diseases · 2026Article
- Advances in Biomarkers and Therapeutic Targets for Idiopathic Inflammatory Myopathies Related Lung Disease.Clinical reviews in allergy & immunology · 2026Review
- Management and Prognosis of Anti-MDA5 Dermatomyositis: Insights from a National Multicenter Cohort.Biomedicines · 2026Article
- An interpretable machine learning model integrating clinical and CT radiomic features for the detection of interstitial lung disease in idiopathic inflammatory myopathies.Arthritis research & therapy · 2026Article
- Progression of interstitial lung abnormalities and its impact on mortality in patients with lung cancer resection.Chinese medical journal pulmonary and critical care medicine · 2026Article
- Machine learning for predicting acute exacerbation and mortality in idiopathic inflammatory myopathy-associated interstitial lung disease.Frontiers in medicine · 2026Article
- Distinct phenotypic clusters associated with progressive pulmonary fibrosis in anti-synthetase syndrome-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Beyond overlap: a Ro52-driven glandular-pulmonary phenotype at the interface of Sjögren disease and anti-synthetase syndrome in a multicentre cohort.Frontiers in immunology · 2026Article
- Semiquantitative HRCT scoring: a reliable predictor of rapidly progressive interstitial lung disease in patients with anti-MDA5 positive dermatomyositis.Quantitative imaging in medicine and surgery · 2026Article
- Review
- Prognostic value of pulmonary vessel-related structures in rapid progression of idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study from two centres.BMJ open respiratory research · 2025Article
- A serum biomarker-based index for predicting progressive pulmonary fibrosis in patients with anti-synthetase syndrome: the LOCCM index.Respiratory research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interstitial lung disease (ILD) is frequently observed in anti-melanoma differentiation-associated protein 5 (MDA5) antibody positive dermatomyositis (DM) and anti-synthetase syndrome (ASS), where they often develop a rapidly progressive ILD (RP-ILD) leading to poor prognosis. Objective: The aim of this study was to construct multivariable prediction risk factors for rapid progressive ILD (RP-ILD) in anti-MDA5 positive DM (MDA5 Methods: 333 idiopathic inflammatory myopathy (IIM) associated ILD patients were studied retrospectively. Risk factors for RP-ILD in MDA5 Results: RP-ILD was more prevalent in MDA5 Conclusions: There were significant different mortality and multivariable risk factors for RP-ILD in MDA5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.